<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625011</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 18-052</org_study_id>
    <nct_id>NCT03625011</nct_id>
  </id_info>
  <brief_title>Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy</brief_title>
  <official_title>Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy/Adenoidectomy: Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Healthcare of Atlanta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study: 1) to examine the use of gabapentin in reducing pain in the
      first 48 hours postoperatively including the total amount of narcotics mg/kg given 2) to
      record the time to first analgesic postoperatively and 3) to compare Wong Baker and the 0-10
      numeric pain distress scale scores at 12, 24 and 48 hours postoperatively. We hypothesize one
      15mg/kg (up to 600mg) dose of gabapentin will decrease mean narcotic amounts in mg/kg
      compared to participants who do not receive preoperative gabapentin and will demonstrate a
      decreased mean time to first analgesic as well as to lower mean pain scores for each age
      group at 12, 24 and 48 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double blinded randomized control trial will enroll 50 children age 3-18 years,
      undergoing T/As from a regional healthcare organization. Patients will be receiving either
      one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test
      group will receive the standard narcotic regimen intraoperatively. Additionally, young
      children will receive instruction for Tylenol and Motrin postoperatively while teenagers will
      receive a narcotic prescription. Outcome measurements include: mean Tylenol mg/kg, Motrin
      mg/kg and narcotic mg/kg use. Additional measurements: Mean time to first analgesic. Phone
      interviews with the research nurse for three days postoperatively will elicit pain scores at
      12, 24 and 48 hours postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Narcotic Consumption</measure>
    <time_frame>First 48 hours postoperatively</time_frame>
    <description>To examine the use of gabapentin in reducing pain in the first 48 hours postoperatively including the total amount of narcotics mg/kg(weight and height will be combined to report BMI in kg/m^2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First Analgesic Timing</measure>
    <time_frame>First 48 Hours postoperatively</time_frame>
    <description>To record the time to first analgesic postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale Scores</measure>
    <time_frame>12, 24 and 48 hours postoperatively.</time_frame>
    <description>To compare the Wong- Baker FACES Pain Rating Scale and the 1-10 numeric pain distress scale pain scores at 12, 24 and 48 hours postoperatively. The 0-10 Numeric Pain Distress Pain Scale utilizes number gradations to describe pain for school age children and adolescents. A zero score means the absence of pain while a five describes distressing pain and a ten infers unbearable pain. As for the Wong-Baker FACES Scale, a series of faces can be shown to children over the age of three. The six faces depict facial expressions with zero-no hurt at all, one-hurts just a little bit, two-hurts a little more, three-hurts even more, four-hurts a whole lot, and five- hurts as much as you can imagine. No subscales will be used or combined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tonsillitis</condition>
  <condition>Tonsillectomy</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to either Control Group or Gabapentin Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to either Control Group or Gabapentin Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.</description>
    <arm_group_label>Gabapentin Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participants age 3-18 years

          -  ASA class 1 or 2

          -  elective Tonsillectomy/Adenoidectomy

          -  outpatient setting.

        Exclusion Criteria:

          -  BMI &gt;40kg/m2

          -  history of renal insufficiency, chronic pain

          -  allergy to gabapentin

          -  history of developmental delay
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Calamaro, PhD, CPNP-PC</last_name>
    <role>Study Chair</role>
    <affiliation>Institutional Review Board</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beena Desai</last_name>
    <phone>404-785-2269</phone>
    <email>beena.desai@choa.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret A Gettis, DNP,CPNP-PC</last_name>
    <phone>404-785-8622</phone>
    <email>margaret.gettis@choa.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beena Desai</last_name>
      <phone>404-785-2269</phone>
      <email>beena.desai@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Margaret A. Gettis, DNP,CPNP-PC</last_name>
      <phone>404-785-8622</phone>
      <email>margaret.gettis@choa.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amani S, Abedinzadeh MR. Effects of Oral Gabapentin, Local Bupivacaine and Intravenous Pethidine on Post Tonsillectomy Pain. Iran J Otorhinolaryngol. 2015 Sep;27(82):343-8.</citation>
    <PMID>26568937</PMID>
  </reference>
  <reference>
    <citation>Amin SM. Evaluation of gabapentin and dexamethasone alone or in combination for pain control after adenotonsillectomy in children. Saudi J Anaesth. 2014 Jul;8(3):317-22. doi: 10.4103/1658-354X.136417. Retraction in: Saudi J Anaesth. 2018 Oct-Dec;12(4):662.</citation>
    <PMID>25191179</PMID>
  </reference>
  <reference>
    <citation>Amin SM, Amr YM. Comparison between preemptive gabapentin and paracetamol for pain control after adenotonsillectomy in children. Anesth Essays Res. 2011 Jul-Dec;5(2):167-70. doi: 10.4103/0259-1162.94758.</citation>
    <PMID>25885382</PMID>
  </reference>
  <reference>
    <citation>Hwang SH, Park IJ, Cho YJ, Jeong YM, Kang JM. The efficacy of gabapentin/pregabalin in improving pain after tonsillectomy: A meta-analysis. Laryngoscope. 2016 Feb;126(2):357-66. doi: 10.1002/lary.25636. Epub 2015 Sep 25. Review.</citation>
    <PMID>26404562</PMID>
  </reference>
  <reference>
    <citation>Knipper E, Banta-Green CJ, Jimenez N. Opioid use disorder and misuse: A review of the epidemiology and medical implications for pediatric anesthesiologists. Paediatr Anaesth. 2017 Nov;27(11):1070-1076. doi: 10.1111/pan.13225. Review.</citation>
    <PMID>29030938</PMID>
  </reference>
  <reference>
    <citation>Mohamed, M.H., Al-Sercy, H. (2014). Preoperative gabapentin decreases the incidence of postoperative vomiting and analgesic requirements after pediatric adenotonsillectomy. The Egyptian Journal of Otolaryngology. 225-228.</citation>
  </reference>
  <reference>
    <citation>Thiels CA, Anderson SS, Ubl DS, Hanson KT, Bergquist WJ, Gray RJ, Gazelka HM, Cima RR, Habermann EB. Wide Variation and Overprescription of Opioids After Elective Surgery. Ann Surg. 2017 Oct;266(4):564-573. doi: 10.1097/SLA.0000000000002365.</citation>
    <PMID>28697049</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Healthcare of Atlanta</investigator_affiliation>
    <investigator_full_name>Margaret Gettis</investigator_full_name>
    <investigator_title>Nurse Scientist</investigator_title>
  </responsible_party>
  <keyword>Pain Relief</keyword>
  <keyword>Non-Narcotic Pain relief</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillitis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03625011/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03625011/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

